Nanocarrier-encapsulated SGLT-2 inhibitor (dapagliflozin) protects against diabetic cardiomyopathy by reducing myocardial fibrosis
Chung‐Yi Li, Fang Xu, Lian Zhu, Chin-Chang Cheng, Jian Kuang, Tong Zhao
Abstract
European Cells & Materials Journal - Open and Free Access - The Official Research Journal of AOCMF, AOTrauma, European Orthopaedic Research Society (EORS), Swiss Society for Biomaterials (SSB) and Tissue & Cell Engineering Society (TCES)
Topics & Concepts
DapagliflozinDiabetic cardiomyopathyMedicineNanocarriersFibrosisMyocardial fibrosisCardiologyCardiomyopathyCardiac fibrosisInternal medicineDiabetes mellitusPharmacologyHeart failureType 2 diabetesEndocrinologyDrugDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsPharmacology and Obesity Treatment